Treatment and Outcome of Patients with Graves' Disease and Metastatic Differentiated Thyroid Cancer

Abstract

Background: The aim of our study was to report on our experience about the treatment and outcome of patients with Graves' disease (GD) and metastatic thyroid cancer in our country.

Methods: Altogether, 28 patients (eight males, 20 females; 49–85 years of age; median 74 years) were treated because of differentiated thyroid cancer and distant metastasis at the time of diagnosis during a 10-year period (from 2010 to 2019) in the Republic of Slovenia. The subject of our retrospective study were four patients (three men, one female; 64-76 years of age, median 73 years) who had Graves' disease and metastatic thyroid cancer.

Results: The mean age of patients without GD and with GD was 74 years and 71 years, respectively (p=0.36). There was a trend for male predominance in patients with GD (p=0.06). There was no statistical difference in size of primary tumors, pT stage or pN stage between the group of patients without GD and with GD. The median length of follow-up was 3.33 years (range 0.04–7.83) and 5-year disease-specific survival was 51%. One of four patients with GD and 14 of 24 patients without GD died of thyroid cancer. There was no statistical difference in disease-specific survival between patients group of without GD and with GD (p=0.59).

Conclusions: In our country, 14% of patients with metastatic differentiated thyroid carcinoma at the time of diagnosis had Graves’ disease. There was no difference in the treatment, outcome or survival of patients with GD in comparison to those without GD.